Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Pfizer

Status and phase: Completed; Phase 1

Conditions: Sarcoma, Ewing's

Treatments: Drug: CP-751,871

Study type: Interventional

Funder types: Industry

Identifiers

NCT00474760

A4021010

Details and patient eligibility

About

This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).

Enrollment: 65 patients

Sex: All

Ages: 9+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Ewing's sarcoma family tumors

Exclusion criteria

• Concurrent treatment with any other anti tumor agents

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

65 participants in 1 patient group

1

Experimental group

Treatment:

Drug: CP-751,871